Santhera Pharmaceuticals Holding Past Earnings Performance
Past criteria checks 0/6
Santhera Pharmaceuticals Holding's earnings have been declining at an average annual rate of -9%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 40.1% per year.
Key information
-9.0%
Earnings growth rate
41.9%
EPS growth rate
Biotechs Industry Growth | 18.9% |
Revenue growth rate | -40.1% |
Return on equity | n/a |
Net Margin | -1,253.2% |
Next Earnings Update | 25 Apr 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Santhera Pharmaceuticals Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 5 | -65 | 27 | 17 |
31 Mar 23 | 6 | -68 | 26 | 21 |
31 Dec 22 | 7 | -71 | 25 | 24 |
30 Sep 22 | 4 | -68 | 24 | 29 |
30 Jun 22 | 0 | -65 | 25 | 33 |
31 Mar 22 | -1 | -60 | 23 | 31 |
31 Dec 21 | -2 | -56 | 22 | 30 |
30 Sep 21 | 5 | -56 | 20 | 30 |
30 Jun 21 | 12 | -56 | 18 | 30 |
31 Mar 21 | 13 | -62 | 21 | 32 |
31 Dec 20 | 15 | -68 | 24 | 34 |
30 Sep 20 | 40 | -46 | 29 | 37 |
30 Jun 20 | 65 | -24 | 34 | 40 |
31 Mar 20 | 70 | -21 | 37 | 40 |
31 Dec 19 | 75 | -19 | 39 | 41 |
30 Sep 19 | 55 | -37 | 39 | 41 |
30 Jun 19 | 34 | -54 | 38 | 39 |
31 Mar 19 | 33 | -54 | 39 | 38 |
31 Dec 18 | 32 | -54 | 40 | 38 |
30 Sep 18 | 30 | -58 | 43 | 35 |
30 Jun 18 | 28 | -56 | 45 | 34 |
31 Mar 18 | 26 | -54 | 44 | 30 |
31 Dec 17 | 23 | -52 | 43 | 27 |
30 Sep 17 | 22 | -42 | 38 | 23 |
30 Jun 17 | 23 | -40 | 35 | 21 |
31 Mar 17 | 21 | -38 | 33 | 19 |
31 Dec 16 | 19 | -35 | 31 | 18 |
30 Sep 16 | 15 | -21 | 29 | 16 |
30 Jun 16 | 10 | -6 | 26 | 15 |
31 Mar 16 | 7 | 0 | 21 | 12 |
31 Dec 15 | 4 | 6 | 17 | 10 |
30 Sep 15 | 4 | -3 | 12 | 8 |
30 Jun 15 | 3 | -11 | 8 | 7 |
31 Mar 15 | 3 | -10 | 6 | 6 |
31 Dec 14 | 3 | -8 | 5 | 6 |
30 Sep 14 | 2 | -7 | 4 | 4 |
30 Jun 14 | 1 | -6 | 3 | 3 |
31 Mar 14 | 1 | -6 | 4 | 4 |
31 Dec 13 | 1 | -6 | 4 | 4 |
30 Sep 13 | 2 | -17 | 5 | 5 |
30 Jun 13 | 3 | -29 | 5 | 6 |
Quality Earnings: SANN is currently unprofitable.
Growing Profit Margin: SANN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SANN is unprofitable, and losses have increased over the past 5 years at a rate of 9% per year.
Accelerating Growth: Unable to compare SANN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SANN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.7%).
Return on Equity
High ROE: SANN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.